

About Neil Johnson (MD CREI FRCOG FRANZCOG MRCGP)

Neil Johnson's (MD CREI FRCOG FRANZCOG MRCGP) main research interests are in evidence-based gynaecology and fertility treatments, the fertility aspects of endometriosis (for which he has pioneered the use of lipiodol in New Zealand and internationally), and polycystic ovary syndrome.

Neil previously served on, and latterly chaired, the board of Endometriosis New Zealand from 2004 – 2019 and chaired the Royal Australian & New Zealand College of Obstetricians & Gynaecologists (RANZCOG) Reproductive Endocrinology & Infertility (REI) Subspecialty Training Committee from 2009 – 2012. He was inaugural chair of the ACCEPT (Australasian CREI Consensus Expert Panel on Trial evidence) Group from its inception in 2008 to 2014 and the multicentre clinical trials network REACT-ANZ (Reproduction and Clinical Trials – Australia and New Zealand) from 2006 to 2014. He had the privilege of convening the Montpellier WES consensus on the management of endometriosis in 2011, the Sao Paulo WES consensus on diagnosis and classification of endometriosis in 2014, and the San Antonio WES consensus on specialist care and networks of expertise in endometriosis in 2017.

Neil Johnson was appointed to the board of the World Endometriosis Society in March 2008 and, having served as its Vice President from 2011-2014, was appointed President Elect in April 2014, and was President from May 2017 through May 2021. He is also the New Zealand representative to and an executive board member of the Asia Pacific Initiative on Reproduction (ASPIRE).